This study evaluated the risks of neurodegenerative disease, including Alzheimer disease, in women with breast cancer treated with hormone modifying therapy.
Assessment of a subgroup of a cohort study revealed that many patients undergoing tamoxifen therapy for early-stage breast cancer do not adhere to their prescribed treatment, even though they claim adherence on patient surveys.
In a randomization of women with early-stage breast cancer, researchers explored the potential benefits of chemotherapy for women whose Oncotype DX RS was midrange.
Researchers report on a study investigating effects of ADT on prostate cancer health-related quality of life, sexual function, sexual bother, and mood for patients with prostate cancer and their partners.
[Breast Cancer: Targets and Therapy] Researchers present a review of the LHRH agonist triptorelin and the use of this agent to induce chemical castration in estrogen-sensitive breast cancer tumors in younger women.
In this study, researchers determined the efficacy of calcitriol, weight-bearing exercise, both, or daily multivitamins on bone formation and resorption in breast cancer survivors actively maintained on hormone therapy.
Women should be encouraged to optimize lifestyle and should not generally be treated with hormone therapy following breast cancer.
The risk of cardiovascular disease such as heart failure, arrhythmias, and conduction disorders are greater in men with localized prostate cancer who were treated with androgen deprivation therapy.
Osteoporosis medications were found to reduce bone mineral density loss and risk of fracture in men with nonmetastatic prostate cancer being treated with androgen-deprivation therapy.
How the body metabolizes next-generation anti-androgen agents affects their anti-tumor activity in the treatment of prostate cancer.
